A targeted gene expression biomarker predicts clinic low-risk meningioma recurrence
Targeted gene expression profiling can identify clinical low-risk meningiomas that are likely to recur after surgery.
Authors
- Calixto‐Hope G. Lucas (ORCID: https://orcid.org/0000-0002-8347-9592)
- David Ronan Raleigh (ORCID: https://orcid.org/0000-0001-9299-8864)
- Craig Horbinski (ORCID: https://orcid.org/0000-0001-8340-9992)
- Mark W. Youngblood (ORCID: https://orcid.org/0000-0002-1044-8015)
- Ramin A. Morshed (ORCID: https://orcid.org/0000-0001-8464-6041)
- Joshua D. Palmer (ORCID: https://orcid.org/0000-0003-3311-0129)
- Stephen T. Magill (ORCID: https://orcid.org/0000-0002-5257-7835)
- Haley Kopp Perlow (ORCID: https://orcid.org/0000-0001-8667-0782)
- William C. Chen (ORCID: https://orcid.org/0000-0001-8924-5853)
- Akash J. Patel (ORCID: https://orcid.org/0000-0002-1280-2989)
- Minh Nguyen (ORCID: https://orcid.org/0000-0001-9665-7629)
Institutions
- Northwestern University (US)
- Johns Hopkins University (US)
- University of California, San Francisco (US)
- Baylor College of Medicine (US)
- Johns Hopkins Medicine (US)
- Northwestern University (PH)
- Ohio State University Hospital (US)
- Neurological Research Institute (US)
- Northwestern Medicine (US)
- Texas Children's Hospital (US)
- Neurological Surgery (US)
- The Ohio State University (US)
Publication Details
- Journal
- Neuro-Oncology
- Published
- 2024-09-28
- DOI
- https://doi.org/10.1093/neuonc/noae198
- Citations
- 8
- Primary Topic
- Meningioma and schwannoma management
- Type
- article
- Field-Weighted Citation Impact
- 3.09
Funders
- National Institutes of Health